Venglustat, Emerging Drug Insight and Market Forecast - 2032

“Venglustat, Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Venglustat for Fabry Disease in the 7MM. A detailed picture of the Venglustat for Fabry Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Venglustat for Fabry Disease. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Venglustat market forecast, analysis for Fabry Disease in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Fabry Disease.

Drug Summary

Venglustat (also known as ibiglustat) is an orally administered small molecule being developed for several rare diseases. It is an inhibitor of an enzyme called Glucosylceramide synthase (GCS) and modifies the enzyme substrates. GCS turns its substrate, ceramide, into Glucosylceramide (GL-1) during lipid metabolism, a series of biochemical reactions that degrade and generate lipids. GL-1 acts as a substrate to other enzymes and is turned into globosides, a subclass of lipids where Gb3 belongs.

When venglustat inhibits GCS, it prevents the synthesis of GL-1, thereby reducing the substrate of the following reactions that lead to the formation of Gb3 and its accumulation in the absence of α-galactosidase A. Due to this mechanism of action venglustat is called a substrate reduction therapy.

The molecule is developed by Sanofi Genzyme and is in the Phase III stage of development for FD. The company expects to file submission by 2025+.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Venglustat description, mechanism of action, dosage and administration, research and development activities in Fabry Disease.
• Elaborated details on Venglustat regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Venglustat research and development activity in Fabry Disease in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Venglustat.
• The report contains forecasted sales of Venglustat for Fabry Disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Fabry Disease.
• The report also features the SWOT analysis with analyst views for Venglustat in Fabry Disease.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Venglustat Analytical Perspective

In-depth Venglustat Market Assessment

This report provides a detailed market assessment of Venglustat in Fabry Disease in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data for the Venglustat.

Venglustat Clinical Assessment

The report provides the clinical trials information of Venglustat in Fabry Disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Fabry Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Venglustat dominance.
• Other emerging products for Fabry Disease are expected to give tough market competition to Venglustat and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Venglustat in Fabry Disease.
• Our in-depth analysis of the forecasted sales data of Venglustat will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Venglustat in Fabry Disease.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Venglustat?
• What is the clinical trial status of the study related to Venglustat in Fabry Disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Venglustat development?
• What are the key designations that have been granted to Venglustat for Fabry Disease?
• What is the forecasted market scenario of Venglustat for Fabry Disease?
• What are the forecasted sales of Venglustat in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Fabry Disease and how are they giving competition to Venglustat for Fabry Disease?
• Which are the late-stage emerging therapies under development for the treatment of Fabry Disease?